Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

10x Genomics (TXG) EBT Margin (2018 - 2025)

10x Genomics (TXG) has disclosed EBT Margin for 8 consecutive years, with 9.15% as the latest value for Q4 2025.

  • Quarterly EBT Margin rose 2017.0% to 9.15% in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 6.21% through Dec 2025, up 2289.0% year-over-year, with the annual reading at 6.21% for FY2025, 2289.0% up from the prior year.
  • EBT Margin hit 9.15% in Q4 2025 for 10x Genomics, up from 18.93% in the prior quarter.
  • In the past five years, EBT Margin ranged from a high of 21.4% in Q2 2025 to a low of 59.71% in Q3 2023.
  • Historically, EBT Margin has averaged 24.28% across 5 years, with a median of 23.46% in 2024.
  • Biggest five-year swings in EBT Margin: soared 35299bps in 2021 and later plummeted -4710bps in 2022.
  • Year by year, EBT Margin stood at 11.14% in 2021, then grew by 6bps to 10.5% in 2022, then plummeted by -141bps to 25.33% in 2023, then dropped by -16bps to 29.32% in 2024, then soared by 69bps to 9.15% in 2025.
  • Business Quant data shows EBT Margin for TXG at 9.15% in Q4 2025, 18.93% in Q3 2025, and 21.4% in Q2 2025.